Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Quoc Truong (NPI 1518922814)

Field	Value
Entity Type	Individual
Organization	Quoc Truong
Address	818 N Enmporia
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 19, 2006

Payer Source	Total Paid
Medicare	$3.9M
Medicaid	$0

Key Findings

This provider’s Medicare billing profile is consistent with an infusion-based hematology/oncology practice: high-revenue monoclonal antibody and immunotherapy codes (notably J9271, J9022, J9145 and J9299) dominate the mix and the chemotherapy administration code 96413 appears among the top-coded services. The presence of supportive-care agents such as J0897 and growth-factor products further supports a service line centered on systemic cancer therapy rather than primarily outpatient primary care visits.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 52.2% of this provider’s total Medicare revenue, with J9271 alone representing 33.7% of Medicare revenue, J9022 10.6%, and J0897 8.0%. That level of concentration indicates the practice derives the majority of its Medicare dollars from a narrow set of high-cost oncology drugs and infusions.

The provider’s payer mix is effectively single-payer on record: lifetime Medicare revenue is $3.9M while there is no Medicaid billing on file. This absence of Medicaid activity means the practice’s publicly reported reimbursement exposure is concentrated in Medicare, which could amplify financial sensitivity to Medicare reimbursement changes affecting high-cost oncology drugs.

Several codes are labeled as “notably above typical national volume,” signaling unusually high throughput in particular areas: J0897 (denosumab) is 95th percentile, 96413 (chemotherapy administration) is 97th percentile, 99213 (office established visit) is 96th percentile, 96367 (additional infusion) is 96th percentile, J0185 is 96th percentile, and 99441 is 99th percentile. Together these high-percentile entries suggest above-typical volume for both infusion-related services and certain E/M or telehealth interactions compared with national peers, consistent with a busy oncology infusion site.

By contrast, the single largest revenue driver J9271 (pembrolizumab) generates $1.2M and 33.7% of Medicare revenue but is ranked #142 of 1841 providers (92th percentile) and labeled “typical, unremarkable volume.” In other words, pembrolizumab is the practice’s dominant revenue source without making the provider an extreme national outlier for that drug’s utilization.

The code mix shows adoption of biosimilars and a range of supportive agents: Q5107 (bevacizumab biosimilar) and Q5108 (pegfilgrastim biosimilar) appear in the top codes alongside J1568 (IV immune globulin), J1449 (eflapegrastim), and J2796 (romiplostim). This combination indicates the practice delivers both high-cost oncologic biologics and the ancillary supportive therapies required for comprehensive cancer care.

Imaging and diagnostics contribute meaningfully but are secondary to drug/infusion revenue: 78815 (PET/CT fusion) accounts for $129.6K (3.6% of Medicare revenue) and A9552 (FDG dose) $13.4K (0.4%). These entries are consistent with a practice that either performs or routinely orders advanced oncologic imaging in support of systemic therapy decision-making.

The provider has a long Medicare enrollment history (NPI enumerated 2006-04-19, ~20 years ago), which, combined with $3.9M in lifetime Medicare revenue, indicates sustained Medicare activity over time. The longevity and the high concentration in oncology infusions suggest an established specialty practice with steady procedural and drug-based Medicare billing rather than a newly opened or primarily consultative-only clinician.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

101 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	28,600	$40	$1.2M
J9022	Injection, atezolizumab, 10 mg	6,020	$60	$385.5K
J0897	Injection, denosumab, 1 mg	16,140	$20	$290.5K
J9145	Injection, daratumumab, 10 mg	5,940	$50	$279.2K
J9299	Injection, nivolumab, 1 mg	10,500	$20	$252K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,500	$40	$175.5K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	120	$1,070	$129.6K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,570	$30	$121.4K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	4,440	$20	$102.1K
J2796	Injection, romiplostim, 10 micrograms	1,350	$70	$98.2K

Showing 1–10 of 101

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 101 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Quoc Truong — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

101 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	11	20	28,900	$40	$1.1M
J9299	14	10	24,550	$20	$637.2K
J9145	7	10	6,660	$50	$394.7K
J9022	2	10	3,910	$60	$301.1K
J9144	7	10	6,300	$40	$257.2K
J2796	3	10	2,380	$70	$208.4K
J1568	7	10	3,690	$30	$129K
Q5107	4	10	4,440	$20	$106.5K
J0897	8	180	2,160	$20	$81.5K
J1627	11	10	15,500	$1	$78.7K

Showing 1–10 of 101

Related Providers

Other providers that share a Tax Identification Number (TIN) with Quoc Truong, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Quoc Truong, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M

Quoc Truong — Billing Profile & Reimbursement Data

Sign up for Quoc Truong — Billing Profile & Reimbursement Data policy alerts

Quoc Truong — Billing Profile & Reimbursement Data

Sign up for Quoc Truong — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References